Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) were down 14.5% on Tuesday . The stock traded as low as C$0.27 and last traded at C$0.27. Approximately 438,482 shares traded hands during mid-day trading, a decline of 36% from the average daily volume of 690,023 shares. The stock had previously closed at C$0.31.
Hemostemix Price Performance
The firm has a fifty day moving average of C$0.11 and a two-hundred day moving average of C$0.08. The stock has a market capitalization of C$23.09 million, a P/E ratio of -13.25 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Transports Are Trending Higher: It’s a Golden Time to Buy More
- Stock Dividend Cuts Happen Are You Ready?
- A Hidden Winner in Manufacturing and Energy Set for a Breakout
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Beyond Rigetti: Top 3 Quantum Computing Stock Picks
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
